Article

Navigating the bumpy road ahead: stakeholder perspectives on EU HTAR

This article was originally published on The Evidence Base.

Symposium
As the European Union's Health Technology Assessment Regulation (EU HTAR) prepares to take effect on January 12, 2025, stakeholders across the healthcare ecosystem are faced with a pivotal opportunity to reshape the evaluation and adoption of new medicines and health technologies. The regulation promises a harmonized framework for assessing clinical evidence, reducing redundancies across Member States, and fostering collaboration in health technology assessment. However, the path to achieving these ambitious goals is neither straightforward nor without challenges.
During ISPOR Europe 2024, Herbert Altmann, Vice President, Market Access and Healthcare Consulting Europe at Cencora, led an informative session exploring the topic, “Ready for 2025? How Lessons Learned From National System Reforms Can Guide Our Response to the New EU HTA Regulations.” The discussion focused on recent HTA reforms in Germany, Spain, France and Poland, examining stakeholder readiness for the EU HTAR and how shared experiences can enhance preparedness.

Altmann was joined by an expert panel: Iga Lipska, Chairwoman of the Board at the Health Policy Institute Poland; François Meyer, Former Director at Haute Autorité de Santé (HAS); Oriol Solà-Morales, CEO of Fundació HiTT; Mihai Rotaru, Director Market Access at the European Federation of Pharmaceutical Industries and Associations (EFPIA); and Max Brosa, former Managing Director of Pharmalex Spain.
Man with digital corporate symbols

Webinar

EU HTA – Achieving broad access fast! What will it take for innovative medicines to succeed?

Healthcare in Europe prepares for the EU HTA. Join our discussion on recent national reforms and essential policies to accelerate patient access to groundbreaking medicines. 

Related resources

Three people in a discussion

Checklist

Find out how the right commercialization strategy can fast-track market access
Learn more

Article

How CGT Developers Can Overcome Market Access, Regulatory, and Commercialization Hurdles
Learn more
iStock-1180547351

Product overview

Introducing FormularyDecisions Product Perspectives
Learn more

We’re here to help

Connect with our team today to learn more about how Cencora is helping to shape the future of healthcare.

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.